Ton Logtenberg
Président chez Synox Therapeutics Ltd.
Profil
Ton Logtenberg was the founder of Crucell NV, founded in 2000, where he held the title of Chief Scientific Officer & Executive VP from 2000 to 2003.
He was also the founder of Merus NV, founded in 2003, where he served as President, Chief Executive Officer & Director.
Currently, Dr. Logtenberg holds several positions.
He is the Chairman of Mestag Therapeutics Ltd.
since 2022.
He is also the Non-Executive Chairman of Synox Therapeutics Ltd.
since 2021.
Additionally, he serves as the Director of Jenner Vaccine Foundation since 2008 and the Director of Utrecht Science Park since 2014.
Furthermore, Dr. Logtenberg is a Venture Partner at Forbion Capital Partners Management Holding BV since 2022 and a Member-Supervisory Board at Hubrecht Organoid Technology Foundation since 2018.
Dr. Logtenberg has previously worked as an Independent Non-Executive Director at Forbion European Acquisition Corp.
and as a Professor at the University of Utrecht.
Dr. Logtenberg obtained a doctorate degree from the University of Utrecht.
Postes actifs de Ton Logtenberg
| Sociétés | Poste | Début |
|---|---|---|
| Utrecht Science Park | Directeur/Membre du Conseil | 01/11/2014 |
| Jenner Vaccine Foundation | Directeur/Membre du Conseil | 01/01/2008 |
| Hubrecht Organoid Technology Foundation | Directeur/Membre du Conseil | 01/08/2018 |
Synox Therapeutics Ltd.
 Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Président | 27/07/2021 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 31/03/2022 |
Mestag Therapeutics Ltd.
 Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Président | 20/12/2022 |
Anciens postes connus de Ton Logtenberg
| Sociétés | Poste | Fin |
|---|---|---|
| MERUS N.V. | Directeur Général | 31/12/2019 |
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Fondateur | 01/11/2003 |
| FORN EUROPAR | Directeur/Membre du Conseil | - |
| ░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Ton Logtenberg
| University of Utrecht | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERUS N.V. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
| Jenner Vaccine Foundation | |
| Utrecht Science Park | |
| Hubrecht Organoid Technology Foundation | |
Mestag Therapeutics Ltd.
Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Finance |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Health Technology |
Forbion European Acquisition Corp.
 Forbion European Acquisition Corp. Financial ConglomeratesFinance Forbion European Acquisition Corp. is a blank check company. It engages in the business of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded by Hugo Alexander Slootweg in 2006 and is headquartered in Wilmington, DE. | Finance |
